Eligo Bioscience Secures $5 Million for Genetic Medicine Advances
Deal News | May 13, 2025 | PR Newswire Cision Eligo Bioscience
Eligo Bioscience, a Paris-based biotechnology company, has been awarded a $5 million grant by the French government's Bpifrance. This funding is part of the 'Innovations in Biotherapies and Bioproduction' initiative under France's 2030 strategy. The grant will support Eligo's development and scale-up of its proprietary gene delivery platform designed for immuno-dermatology applications. Eligo's technology involves using skin-resident bacteria to locally produce therapeutic biologics, enhancing treatment precision for conditions like acne vulgaris. The company plans to optimize its bioproduction processes in collaboration with Biose Industries, aiming for expanded clinical trials. This financial boost follows Eligo's recent achievements, including expanding its Series B funding to $35 million and securing key patents for skin microbiome engineering.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- France – Eligo Bioscience is based in Paris, and the funding is provided by the French government through Bpifrance.
Industry
- Biotechnology – Eligo Bioscience operates within this industry as it develops genetic medicine platforms for medical applications.
- Pharmaceuticals – The article discusses the development of therapeutic biologics, which falls under the pharmaceutical industry, particularly for dermatological applications.
- Healthcare – The company's focus on developing treatments for immuno-dermatological conditions aligns with the healthcare industry's goals of addressing medical challenges.
Financials
- $5 million – Grant provided to Eligo Bioscience by the French government via Bpifrance.
- $35 million – Eligo Bioscience's expanded Series B funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Eligo Bioscience | Target Company | Company | A biotechnology company focused on developing novel genetic medicine platforms, particularly for skin diseases. |
| Bpifrance | Funder | Government | The French public investment bank that provided the $5 million grant as part of a national strategy. |
| Biose Industries | Manufacturing Partner | Company | A CDMO specializing in microbial fermentation, assisting Eligo with scaling up production processes. |